The goal of this study is to learn about how the hormone insulin controls blood sugar. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. People with obesity and high insulin levels will receive eight doses of diazoxide, a drug that suppresses the pancreas's production of insulin, and will have their fasting blood sugar and insulin levels checked daily while taking the drug.

Start Date23 Oct 2024

Sponsor / Collaborator

Columbia University

[+1]

NCT06308107 / RecruitingPhase 1IIT

Safety and Feasibility of Hyperkalemic Cardioplegia With Diazoxide in Cardiac Surgery (CPG-DZX) Trial

This study aims to confirm the safety and efficacy of diazoxide as an additive to hyperkalemic cardioplegia in patients undergoing cardiac surgery with cardiopulmonary bypass. The investigators hypothesize that diazoxide combined with hyperkalemic cardioplegia provides superior myocardial protection and reduced myocardial stunning compared with standard cardioplegia alone. Thirty patients will receive treatment. Safety will be assessed by comparing mean arterial blood pressure measurements, glucose levels and incidence of adverse events between the two groups. Efficacy will be assessed by comparing right and left ventricular function in pre-operative vs post-operative transesophageal echocardiograms, need for mechanical circulatory support, ease of separation from bypass and Vasoactive Inotrope Score (VIS) between the two groups. The information gained could pave the way for the use of Katp (Potassium-atp) channel openers to prevent stunning, improve patient outcomes, and reduce health care costs related to myocardial stunning that requires inotropic and mechanical support following cardiac surgery.

Start Date08 Jul 2024

Sponsor / Collaborator

The Johns Hopkins University

TCTR20240731001 / RecruitingPhase 3IIT

Scientific Title: Evaluation of the Clinical Efficacy and Safety of Dexmedetomidine Combined with Diazoxide for Anesthesia in Vaginal Ultrasound-Guided Egg Retrieval in IVF-ET Procedures

Start Date01 Jul 2024

Sponsor / Collaborator-

100 Clinical Results associated with Diazoxide

100 Translational Medicine associated with Diazoxide

100 Patents (Medical) associated with Diazoxide

3,660

Literatures (Medical) associated with Diazoxide

02 Jan 2025·Rhode Island medical journal

Management of Neonatal Hyperinsulinemic Hypoglycemia: Trends Over Nine Years.

Article

Author: Fredette, Meghan E ; Tanzer, Joshua Ray ; Topor, Lisa Swartz ; Pillai, Sabitha Sasidharan

BACKGROUND:

With increasing use of diazoxide for hyperinsulinemic hypoglycemia (HH), reporting of serious side effects of diazoxide such as pulmonary hypertension (PHT) increased.

METHODS:

Charts of all children diagnosed with HH during the study period and evaluated by Pediatric Endocrinology division of the Hasbro Children's Hospital were reviewed. We analyzed diazoxide use among infants with HH with focus on infants born small for gestational age (SGA) and preterm infants.

RESULTS:

Average timing of diazoxide initiation was later after 6/2017 compared to prior in preterm infants (45 days versus 4 days, p < 0.001) and in SGA infants (28 days versus 13 days, p < 0.001). Prescribing patterns changed further over time, corresponding with development of diazoxide-associated PHT in three infants between 10/2018-5/2020. Delays in diazoxide initiation were observed after 5/2020 compared to prior in full-term, non-SGA infants: 18 days versus12 days (p = 0.01). The proportion of SGA infants who received diazoxide was lower after 5/2020 compared to prior (23% versus 65%, p = 0.03). PHT developed in 12.5% of infants treated with diazoxide in this cohort, 75% of whom were preterm and/or SGA, and 75% were born to mothers with preeclampsia.

CONCLUSIONS:

Patterns of diazoxide use changed over time, with delayed use in preterm and/or SGA infants observed after 6/2017, reduced use in SGA infants, and delayed initiation in all infants after 5/2020. PHT was not rare in our cohort, and was more likely in infants born SGA, preterm, or to a mother with preeclampsia.

15 Nov 2024·Cureus Journal of Medical Science

A Rare and Aggressive Case of Malignant Insulinoma

Article

Author: Gonçalves, Francisco ; Silva, Catarina R ; Duarte, Daniela

Insulinomas are rare pancreatic neuroendocrine tumors (NETs) characterized by autonomous insulin secretion leading to hypoglycemia. Malignant insulinomas are defined by the presence of metastases and present significant therapeutic challenges due to limited treatment options. We report the case of a 69-year-old woman with a two-month history of neuroglycopenic symptoms, including morning headaches, blurred vision, palpitations, and sweating, which were alleviated by sugar intake. An episode of severe hypoglycemia-induced unconsciousness necessitated intramuscular glucagon administration, resulting in regained consciousness. The combination of neuroglycopenic symptoms relieved by carbohydrate and documented hypoglycemia fulfilled Whipple's triad, prompting evaluation for an insulin-secreting tumor. Laboratory findings revealed elevated endogenous insulin and C-peptide levels, indicating hyperinsulinemia. Imaging studies, including contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), identified a 25 mm solid lesion in the pancreatic body and multiple hepatic metastases. A ⁶⁸Ga-DOTA-NOC positron emission tomography (PET) scan demonstrated high somatostatin receptor expression in both the pancreatic lesion and hepatic metastases. Ultrasound-guided liver biopsy revealed a high-grade (G3) neuroendocrine carcinoma with a Ki-67 proliferation index exceeding 30%, confirming the diagnosis of malignant insulinoma. Multidisciplinary consultation recommended initiation of systemic chemotherapy with cisplatin and etoposide. Despite optimized medical management, including dextrose infusion, diazoxide, octreotide, and corticosteroids, the patient experienced persistent severe hypoglycemia. Transarterial chemoembolization (TACE) of the tumor vasculature was performed to mitigate hypoglycemia by reducing tumor burden. Post-procedure, the patient developed a cerebellar hemorrhage leading to coma and subsequent death. This case underscores the aggressive nature and poor prognosis associated with malignant insulinomas, particularly those with high proliferative indices. It highlights the complexities of managing refractory hypoglycemia in the context of widespread metastatic disease and emphasizes the urgent need for effective therapeutic strategies to improve patient outcomes.

07 Nov 2024·JCEM Case Reports

Diazoxide-Responsive Hypoglycemia in a Child Receiving Dasatinib for Treatment of B-Cell Acute Lymphoblastic Leukemia

Article

Author: Biro, Juliana ; Kashmiri, Himala ; Berra, Madalin ; Daniels, Mark

Abstract:

Tyrosine kinase inhibitors (TKIs) are being used more regularly in treatment regimens for pediatric cancers. They have distinct side effect profiles, including endocrinopathies. Here we present a 2-year-old boy with Philadelphia chromosome–like (Ph-like) B-cell acute lymphoblastic leukemia (ALL) who developed refractory hypoglycemia after using dasatinib. His evaluation was suggestive of hyperinsulinism, and his symptoms were ultimately controlled with diazoxide. There have not been any published data exploring the relationship between TKIs and glycemic profiles in pediatric patients. In adults, there is research indicating that patients using TKIs could experience both hyperglycemia and hypoglycemia. The pathophysiology of these side effects is not well described, nor are the risk factors for development. More research is needed to understand these relationships in general, but particularly in the pediatric population.

News (Medical) associated with Diazoxide

27 Nov 2024

·www.pharmaceutical-technology.com

FDA delays decision of Soleno’s Prader-Willi syndrome drug

The extension allows the FDA time to complete its review. Credit: izzuanroslan via Shutterstock. The US Food and Drug Administration (FDA) has delayed its decision on Soleno Therapeutics investigational therapy for children with Prader-Willi syndrome. The new decision date for Soleno’s DCCR (diazoxide choline) extended-release tablets is set for 27 March 2025 – three months longer than the previous FDA extended review period. The delay comes after the FDA classified recent responses from Soleno as a “major amendment” to its new drug application (NDA), requiring additional time to review. However, the agency has not raised concerns about the drug’s safety, efficacy, or manufacturing. Prader-Willi syndrome is a rare genetic disorder caused by abnormalities in chromosome 15. Symptoms include low muscle tone, developmental delays, and behavioural challenges. Hyperphagia, or extreme hunger, is one of the most serious and defining characteristics of the disorder and can lead to severe obesity and associated health complications if unmanaged. There are currently no FDA-approved treatments specifically addressing hyperphagia in Prader-Willi syndrome. The US-based biotech’s NDA is supported by data from the Phase III DESTINY-PWS trial (NCT03440814), which enrolled 127 individuals with genetically confirmed Prader-Willi syndrome. The trial did not demonstrate a statistically significant difference in hyperphagia reduction overall, but Soleno said that the DCCR group showed “nominally significant” reductions in fat mass, and overall improvements in condition as assessed by investigators. DCCR has been granted breakthrough therapy, fast track, and orphan drug designations in the US, as well as orphan drug designation in the EU. Originally slated for discussion at an FDA advisory committee (AdComm) meeting, the agency decided in October 2024 that such a meeting was unnecessary. DCCR is an extended-release tablet containing a crystalline salt formulation of diazoxide, an activator of the adenosine triphosphate (ATP)-sensitive potassium (KATP) channel. These channels are present in a variety of cells, including pancreatic β cells, and adipocytes. The regulation of these cells can help manage hyperphagia. The delay represents a setback for Soleno on its first potential approved treatment. Soleno’s stock price decreased by 6.9% from $57.22 at close on 25 November to a low of $53.25 on 26 November. According to GlobalData’s Pharma Intelligence Center, DCCR could generate up to $759m in sales by 2030. GlobalData is the parent company of Pharmaceutical Technology. The company is also evaluating DCCR as a treatment for paediatric patients with certain genetic obesities, including SH2B1 deficiency, obesity associated with PCSK1 mutation (rs6232 variant), and SIM1 deficiency. A Phase II trial (NCT05532020) is set to enrol approximately 30 patients aged five years or younger suffering from either of the three genetic obesity disorders.

Orphan DrugFast TrackNDAPhase 2Breakthrough Therapy

26 Nov 2024

·www.globenewswire.com

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

PDUFA target action date extended by three months to March 27, 2025REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. The new Prescription Drug User Fee Act (PDUFA) target action date is March 27, 2025. The FDA determined that responses to recent information requests constituted a major amendment to the NDA, resulting in the extension of the PDUFA goal date by three months. The extension allows the FDA time to complete their review, including that of the recently submitted information. The FDA did not cite any safety, efficacy or manufacturing concerns in their correspondence. Soleno submitted the NDA to the FDA on June 27, 2024. The FDA accepted the NDA and granted Priority Review in August 2024. Diazoxide choline has been granted Breakthrough and Fast Track Designations in the U.S., as well as Orphan Drug Designation in the U.S. and E.U. for the treatment of patients with PWS. About PWSThe Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening condition characterized by feelings of intense, persistent hunger, food pre-occupation, and an extreme drive to seek and consume food, which can severely diminish the quality of life for individuals with PWS and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease. In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parents and caregivers) rated hyperphagia and 92.9% rated body composition as either the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder. About DCCR (Diazoxide Choline) Extended-Release TabletsDCCR is a novel, proprietary extended-release dosage form containing diazoxide choline, the crystalline salt of diazoxide and is administered once-daily. The parent molecule, diazoxide, has been used for decades in thousands of individuals in a few rare diseases in neonates, infants, children and adults, but is not approved for use in PWS. Soleno conceived of and established extensive patent protection for the therapeutic use of diazoxide, diazoxide choline and DCCR in individuals with PWS. The DCCR development program is supported by data from five completed Phase 1 clinical studies in healthy volunteers and three completed Phase 2 clinical studies, one of which was in individuals with PWS. In the PWS Phase 3 clinical development program, DCCR showed promise in addressing hyperphagia, the hallmark symptom of PWS, as well as several other symptoms such as aggressive/destructive behaviors, fat mass and other metabolic parameters. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the FDA’s review of our NDA, market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578

NDAPhase 2Phase 3Fast TrackPriority Review

14 Nov 2024

·www.globenewswire.com

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. Details of the oral presentations are as follows: ESPE 2024 Title:Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in Clinical Trials of Diazoxide Choline Extended-Release (DCCR) in Participants with Prader-Willi SyndromeFormat:Oral PresentationSession:Free Communications 6: Fat, Metabolism and Obesity (1)Date/Time:Sunday, November 17, 2024 at 10:30 AM GMTPresenter:Nicola Bridges, M.D. (Chelsea and Westminster Hospital NHS Trust, London, UK) Title:Long-term Efficacy Results of Diazoxide Choline Extended-Release (DCCR) Tablets in Participants with Prader-Willi Syndrome from the Completed C601 (DESTINY PWS) and C602 Open Label Extension (OLE) StudiesFormat:Oral PresentationSession:Free Communications 11: Fat, Metabolism and Obesity (2)Date/Time:Monday, November 18, 2024 at 10:00 AM GMTPresenter:Evelien Gevers, M.D., Ph.D. (Queen Mary University of London, Barts and The London Medical School, William Harvey Research Institute, Centre for Endocrinology; Parts Health NHS Trust, Royal London Hospital, UK) About PWSThe Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening condition characterized by feelings of intense, persistent hunger, food pre-occupation, and an extreme drive to seek and consume food, which can severely diminish the quality of life for individuals with PWS and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease. In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parents and caregivers) rated hyperphagia and 92.9% rated body composition as either the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder. About DCCR (Diazoxide Choline) Extended-Release TabletsDCCR is a novel, proprietary extended-release dosage form containing diazoxide choline, the crystalline salt of diazoxide and is administered once-daily. The parent molecule, diazoxide, has been used for decades in thousands of individuals in a few rare diseases in neonates, infants, children and adults, but is not approved for use in PWS. Soleno conceived of and established extensive patent protection for the therapeutic use of diazoxide, diazoxide choline and DCCR in individuals with PWS. The DCCR development program is supported by data from five completed Phase 1 clinical studies in healthy volunteers and three completed Phase 2 clinical studies, one of which was in individuals with PWS. In the PWS Phase 3 clinical development program, DCCR showed promise in addressing hyperphagia, the hallmark symptom of PWS, as well as several other symptoms such as aggressive/destructive behaviors, fat mass and other metabolic parameters. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the FDA’s review of our NDA, market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578

Phase 2Phase 3Clinical ResultNDAPriority Review

100 Deals associated with Diazoxide

External Link

KEGG	Wiki	ATC	Drug Bank
D00294	Diazoxide	V03AH01 C02DA01	DB01119

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	US	Schering Corp.	22 Jan 1973
Hypoglycemia	US	Schering Corp.	22 Jan 1973

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis	Phase 2	ES	Neurotec Pharma SL	-
Amyotrophic Lateral Sclerosis	Preclinical	ES	Neurotec Pharma SL	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SAT157 (ENDO2023)	Not Applicable	Chronic Kidney Diseases	4	Diazoxide 50 mg TID	atdudxfbsd(ezgnbgjklz) = rzrmxfydfu ifnchmwnff (ujfityeuhk ) View more	Positive	05 Oct 2023
				Diazoxide 70 mg BID	atdudxfbsd(ezgnbgjklz) = iedyuegvyi ifnchmwnff (ujfityeuhk ) View more
PSUN340 (ENDO2022)	Not Applicable	Congenital Hyperinsulinism ABCC8 \| KCNJ11 \| GCK ... View more	2	diazoxide (Case 1)	gtoywwheks(njsildjiai) = ztctlkbhci qamfbinjrp (ngamopdbft ) View more	-	01 Nov 2022
				diazoxide (Case 2)	gtoywwheks(njsildjiai) = wljerviqfm qamfbinjrp (ngamopdbft ) View more
ESPE2022	Not Applicable	Congenital Hyperinsulinism HADH mutation	-	Diazoxide	fsoxqwrqoz(qksuvxvguc) = drlekoojyf rmcvyjfhpa (wjcdgczfdb, 0.9 - 7.1) View more	-	15 Sep 2022
				Diazoxide	lweetptlva(yqqcrcdvrq) = vlxzrcxbon iijevotxwl (szikzxedfn )
ESPE2022	Not Applicable	Hemochromatosis	99	Diazoxide 2mg/kg/day	eojaujvjng(nzazuxwwfi) = Adverse events can still be observed with DZX low doses, but at a lower incidence compared to the STD jykuemxskv (zgfsnjgwhe ) View more	Positive	15 Sep 2022
				Diazoxide 3mg/kg/day
ENDO2021	Not Applicable	Glut1 Deficiency Syndrome SLC2A1	1	Diazoxide	hnsigvnbkt(zqrkwjkgqn) = uypvyvoqfp ahetwullkj (fcgiwcuhdf ) View more	Positive	03 May 2021
				Diazoxide (Ketogenic Diet)	hnsigvnbkt(zqrkwjkgqn) = txiyplbjvk ahetwullkj (fcgiwcuhdf ) View more
ENDO2021	Not Applicable	-	46	Diazoxide	lwrqvxdqzm(lkcgjfatwf) = nbpyjmqrwf yfxxyxynow (qylfsuxoce ) View more	Positive	03 May 2021
MON-073 (ENDO2020)	Not Applicable	ABCC8 Dominant Mutation	-	Diazoxide (ABCC8 Dominant Mutation)	qzrdtnmgaf(dbwksyobux) = lyhtvcryyl tptagtffum (cdyybxpvtw ) View more	-	08 May 2020
ESPE2019	Not Applicable	Congenital Hyperinsulinism ABCC8 \| KCNJ11	-	Diazoxide	tuhybhequk(rabqrhojpt) = due to vomiting on oral feeds lrbraghdaq (blpsslwsac ) View more	-	19 Sep 2019
ESPE2019	Not Applicable	Congenital Hyperinsulinism	-	Diazoxide	jzcnlwijhy(pbiioxnbsi) = eghqtjssbo uwbzdlkumm (iisgjeqtzm )	-	19 Sep 2019
				Octreotide	jzcnlwijhy(pbiioxnbsi) = bhqdopcfpj uwbzdlkumm (iisgjeqtzm )
SAT-271 (ENDO2019)	Not Applicable	C-peptide levels \| glucose requirements	141	Diazoxide-treated neonates	anffscsoqz(othvqsnhkh) = iprxlrwzvu ockvoyhmuq (phayctsiyz ) View more	Positive	30 Apr 2019
				Diazoxide (Untreated neonates)	anffscsoqz(othvqsnhkh) = psbeqfzatx ockvoyhmuq (phayctsiyz ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis